Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer

First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
130
Registration Number
NCT06714357
Locations
🇮🇹

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

First Posted Date
2024-10-29
Last Posted Date
2024-12-18
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
1000
Registration Number
NCT06662786
Locations
🇲🇾

Hospital Pulau Pinang, Georgetown, Malaysia

🇲🇾

Hospital Umum Sarawak, Kuching, Malaysia

🇲🇾

Hospital Raja Permaisuri Bainun, Ipoh, Malaysia

and more 20 locations

A Study of Ifinatamab Deruxtecan in Subjects With Advanced or Metastatic ESCC (IDeate-Esophageal01)

First Posted Date
2024-10-16
Last Posted Date
2024-10-16
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
510
Registration Number
NCT06644781

Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

First Posted Date
2024-10-03
Last Posted Date
2024-12-13
Lead Sponsor
Revolution Medicines, Inc.
Target Recruit Count
460
Registration Number
NCT06625320
Locations
🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

and more 4 locations

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

First Posted Date
2024-09-23
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
750
Registration Number
NCT06607185
Locations
🇨🇳

Hsin-Chu Hospital, Hsin-chu, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 21 locations

A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

First Posted Date
2024-09-19
Last Posted Date
2024-11-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
530
Registration Number
NCT06586515
Locations
🇺🇸

UCLA, Santa Monica, California, United States

🇺🇸

City of Hope Medical Group, South Pasadena, California, United States

🇺🇸

Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States

and more 40 locations

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
34
Registration Number
NCT06547203
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

First Posted Date
2024-08-07
Last Posted Date
2024-11-01
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
114
Registration Number
NCT06541262
Locations
🇺🇸

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

First Posted Date
2024-08-05
Last Posted Date
2024-11-25
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
46
Registration Number
NCT06538207
Locations
🇯🇵

National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

🇯🇵

Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan

🇯🇵

Seirei Hamamatsu General Hospital, Hamamatsu-shi, Shizuoka, Japan

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy